TEL
+ 86-21-6420 0566
Код каталога 80017137
CAS NO.95635-55-5
Чистота 95%
Номер MDLMFCD00864690
Молекулярная формула EINEC C24H33N3O4
Молекулярный вес 427.5365
| Аспект | Подробнее |
|---|---|
| Механизм действия | Ranolazine is a late sodium channel blocker that inhibits the late sodium current (INa,late) in cardiac muscle cells. This action prevents calcium overload, reduces left ventricular wall tension, and increases coronary blood flow, leading to relief of angina. It also stabilizes the myocardial cell membrane, contributing to its anti-arrhythmic effects. |
| Клиническое использование | Ranolazine is primarily used for the treatment of chronic stable angina. It is also being explored for its potential benefits in managing ischemic heart disease, particularly in patients with diabetes mellitus, and for preventing post-cardioversion and post-CABG atrial fibrillation. |
| Лекарственные формы | Available as extended-release tablets in doses of 500 mg and 1000 mg. Typical dosing is 500–1000 mg twice daily. |
| Условия хранения | Should be stored at room temperature, between 68°F to 77°F (20°C to 25°C), and can be exposed to temperatures between 59°F to 86°F (15°C to 30°C) for shorter periods. |
| Побочные эффекты | Common side effects include dizziness, headache, constipation, nausea, and fatigue. More serious adverse effects may include QT prolongation, renal impairment, and allergic reactions. |
| Лекарственное взаимодействие | Ranolazine is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and inducers (e.g., rifampin, St. John’s wort) can significantly alter ranolazine levels. Co-administration with metformin requires careful monitoring of blood glucose levels. |
| Особые соображения | Caution is advised in patients with a history of long QT syndrome or renal impairment. Ranolazine is contraindicated in patients with hepatic cirrhosis and those allergic to the drug. |
| мониторинг | Regular monitoring of the QT interval is recommended, especially when used with other QT-prolonging drugs. Patients should also be monitored for signs of renal impairment and neurologic adverse effects. |
Отказ от ответственности: приведенный выше контент предназначен только для справки и общения среди инсайдеров отрасли и не гарантирует его точность или полноту. Согласно соответствующим законам и правилам, а также правилам этого веб-сайта, подразделения или лица, которые покупают соответствующие товары, должны получить действительные квалификации и условия квалификации.
Фабрика и отгрузка
